Humboldt Pharmaceuticals Holdings Limited (Humboldt Pharm-B) submitted a disclosure report to the Hong Kong Stock Exchange on September 17, 2024, disclosing changes in its shareholding. The report showed that Humboldt Pharm-B repurchased 100,000 ordinary shares on September 17, 2024, accounting for 0.013% of its issued shares. The repurchase price ranged from HKD 1.24 to HKD 1.28 per share, with a total payment of HKD 126,090. After the repurchase, the company's issued shares decreased to 768,226,410 shares, while treasury shares increased to 650,000 shares. The company confirmed that this share repurchase has been approved by the board of directors and complies with all applicable listing rules, laws, and other regulatory requirements. According to the rules, Humboldt Pharm-B is prohibited from issuing new shares or selling or transferring any treasury shares within 30 days after the share repurchase, until October 17, 2024.

Humboldt Pharmaceuticals Holdings Limited (Humboldt Pharm-B) submitted a disclosure report to the Hong Kong Stock Exchange on September 17, 2024, disclosing changes in its shareholding. The report showed that Humboldt Pharm-B repurchased 100,000 ordinary shares on September 17, 2024, accounting for 0.013% of its issued shares. The repurchase price ranged from HKD 1.24 to HKD 1.28 per share, with a total payment of HKD 126,090. After the repurchase, the company's issued shares decreased to 768,226,410 shares, while treasury shares increased to 650,000 shares. The company confirmed that this share repurchase has been approved by the board of directors and complies with all applicable listing rules, laws, and other regulatory requirements. According to the rules, Humboldt Pharm-B is prohibited from issuing new shares or selling or transferring any treasury shares within 30 days after the share repurchase, until October 17, 2024.